Chris Chai and Peter Van Vlasselaer, both former executives at SR One portfolio companies, have been hired by the GSK-backed VC firm as venture partners.

Alphabet's GV unit and Huami both took part as the portable MRI device developer completed an oversubscribed series D round.

The Lepu-backed genetic cancer therapy developer has completed a $94.9m round co-led by CICC Capital, Share Capital, Vertex Ventures China and Qianhai FOF.

Cleva Pharma Capital backed a series C round that will support the clinical progress of drug candidates for sensorineural hearing loss and multiple sclerosis.

Returning backer Novo was among the investors in a series C round for the synthetic cancer treatment developer that was led by RA Capital Management.

Today's deal net contains news from RAW Labs, Neuropain Therapeutics and Swajal.

Swisscom Ventures participated in a round that lifted the total raised by the laboratory simulation software provider to $104m.

The life sciences research technology developer has received funding in a series A round co-led by corporate investor ABclonal.

The past week's M&A exits included Genetirate, DataFleets and SightGlass Vision.

UC Davis's probiotics spinout secured an undisclosed amount as Bow Capital backed the first close of a series D round with a $55m target.